Goldman et al. RTX, TCZ in SSc ILD. 129 patients, 87 RTX, 32 TCZ, 10 both. Median changes in %FVC and %DLCO pre-and post-treatment were +0.35% and -0.8% for rituximab and -0.9% and +0.2% for tocilizumab. Majority stable/improved @RheumNow #ACR22 Abstr#1520 https://t.co/ydY5FGEYnQ https://t.co/O9QD7nkjdZ
Links:
Rituximab and Tocilizumab and Their Effect on Lung Disease Progression in Scler…
https://acrabstracts.org/abstract/rituximab-and-tocilizumab-and-their-effect-on…
13-11-2022